Skip to content
The Policy VaultThe Policy Vault

SovaldiMedica

genotype 2 or 3 chronic hepatitis C virus (HCV) in pediatric patients ≥3 years and <18 years (new start)

Preferred products

  • Epclusa (brand)

Initial criteria

  • Genotype 2 or 3 chronic HCV pediatric patients ≥3 and <18 years (new start): Sovaldi is not approved. Offer to review for Epclusa (brand only) using the standard Hepatitis C – Epclusa PA Policy criteria.
  • Patient continuing therapy with Sovaldi: follow the standard Hepatitis C – Sovaldi PA Policy criteria.

Approval duration

as specified in the respective Hepatitis C policies